Drug Search Results
More Filters [+]

BSI-04702

Alternative Names: BSI-04702, BSI04702, BSI 04702
Latest Update: 2021-12-13
Latest Update Note: Clinical Trial Update

Product Description

BSI-04702 is an anti-TROP2 humanized monoclonal antibody created by Biosion's proprietary SynTracer™ internalization TROP2 is highly expressed in various cancer cells, such as pancreatic, gastric, lung, colorectal cancer cells, and its overexpression is associated with poor survival in patients with solid tumors. In Dec 2021, Biosion licensed ex-Greater China rights of BSI-04702 to OBI Pharma. (Sourced from: https://www.biosion.com/pipeline)

Mechanisms of Action: TROP2 Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biosion
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BSI-04702

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events